Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE

被引：15

作者：

Loibl, Sibylle ^{[1
,2
]}

Huang, Chiun-Sheng ^{[3
,4
]}

Mano, Max S. ^{[5
]}

Mamounas, Eleftherios P. ^{[6
,7
]}

Geyer, Charles E. ^{[8
,9
]}

Untch, Michael ^{[10
,11
]}

Thery, Jean-Christophe ^{[12
]}

Schwaner, Ingo

Limentani, Steven ^{[13
]}

Loman, Niklas ^{[14
]}

Lubbe, Kristina ^{[15
]}

Chang, Jenny C. ^{[16
]}

Hatschek, Thomas ^{[17
]}

Tesarowski, David ^{[18
]}

Song, Chunyan ^{[18
]}

de Haas, Sanne Lysbet ^{[19
]}

Boulet, Thomas ^{[19
]}

Lambertini, Chiara ^{[19
]}

Wolmark, Norman ^{[8
,20
]}

机构：

[1] GBG, Neu Isenburg, Germany

[2] Ctr Haematol & Oncol Bethanien, Frankfurt, Germany

[3] Natl Taiwan Univ Hosp, Taipei, Taiwan

[4] Natl Taiwan Univ, Coll Med, Taipei, Taiwan

[5] Inst Canc Estado Sao Paulo, Sao Paulo, Brazil

[6] NSABP Fdn, Orlando, FL USA

[7] Orlando Hlth Canc Inst, Orlando, FL USA

[8] NSABP Fdn, Pittsburgh, PA USA

[9] Univ Pittsburgh, Hillman Canc Ctr, Pittsburgh, PA USA

[10] AGO B, Berlin, Germany

[11] HELIOS Klinikum Berlin Buch, Berlin, Germany

[12] Ctr Henri Becquerel, Canc Ctr, Rouen, France

[13] Atrium Hlth, Charlotte, NC USA

[14] Skane Univ Hosp, Lund, Sweden

[15] Diakovere Henrietten Stift, Hannover, Germany

[16] Houston Methodist Canc Ctr, Houston, TX USA

[17] Karolinska Univ Hosp, Solna, Sweden

[18] Genentech Inc, San Francisco, CA 94080 USA

[19] F Hoffmann La Roche Ltd, Basel, Switzerland

[20] Univ Pittsburgh, Pittsburgh, PA USA

来源：

NPJ BREAST CANCER | 2022年 / 8卷 / 01期

关键词：

NEOADJUVANT CHEMOTHERAPY; HER2; PROGNOSIS;

D O I：

10.1038/s41523-022-00477-z

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Following chemotherapy and human epidermal growth factor 2 (HER2)-targeted neoadjuvant therapy for HER2-positive early breast cancer, residual invasive breast cancer at surgery may be HER2-negative on retesting in some patients. We evaluated outcomes with T-DM1 and trastuzumab in patients randomized in the phase III KATHERINE trial based on HER2-positive central testing of the pre-treatment core biopsy with HER2-negative central testing on their corresponding surgical specimen after neoadjuvant treatment. In the 70/845 (8.3%) patients with HER2-negative residual disease on retesting at surgery, there were 11 IDFS events in the 42 trastuzumab-treated patients (26.2%) and none in the 28 T-DM1-treated patients, suggesting that T-DM1 should not be withheld in this patient population.

引用

页数：6

共 50 条

[21] Cost-effectiveness analysis of trastuzumab emtansine versus trastuzumab for Chinese patients with residual invasive HER2-positive early breast cancer
Guan, X.
Li, H-C.
Chen, Q-J.
Hua, B.
Li, J-J.
Ma, F.
Wang, Y-S.
Xu, H.
Liu, C.
Yang, Q.
Ma, A-X.
ANNALS OF ONCOLOGY, 2021, 32 : S45 - S45
[22] Trastuzumab emtansine in the treatment of HER2-positive metastatic breast cancer in Japanese patients
Sawaki, Masataka
BREAST CANCER-TARGETS AND THERAPY, 2014, 6 : 37 - 41
[23] Economic evaluation of adjuvant trastuzumab emtansine in patients with HER2-positive early breast cancer and residual invasive disease after neoadjuvant taxane and trastuzumab-based treatment in Canada
Younis, T.
Lee, A.
Coombes, M. E.
Bouganim, N.
Becker, D.
Revil, C.
Jhuti, G. S.
CURRENT ONCOLOGY, 2020, 27 (06) : E578 - E589
[24] Adjuvant Trastuzumab in HER2-Positive Breast Cancer REPLY
Slamon, Dennis J.
Buyse, Marc
Press, Michael F.
NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (07): : 663 - 665
[25] Trastuzumab deruxtecan versus trastuzumab emtansine in Asian patients with HER2-positive metastatic breast cancer
Iwata, Hiroji
Xu, Binghe
Kim, Sung-Bae
Chung, Wei-Pang
Park, Yeon Hee
Kim, Min Hwan
Tseng, Ling-Ming
Chung, Chi-Feng
Huang, Chiun-Sheng
Kim, Jee Hyun
Chiu, Joanne Wing Yan
Yamashita, Toshinari
Li, Wei
Egorov, Anton
Nishijima, Soichiro
Nakatani, Shunsuke
Nishiyama, Yuji
Sugihara, Masahiro
Cortes, Javier
Im, Seock-Ah
CANCER SCIENCE, 2024,
[26] Trastuzumab emtansine (T-DM1) versus trastuzumab in Chinese patients with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy for HER2-positive breast cancer in the phase 3 KATHERINE study
Huang, Chiun-Sheng
Yang, Youngsen
Kwong, Ava
Chen, Shin-Cheh
Tseng, Ling-Ming
Liu, Mei-Ching
Shen, Kunwei
Wang, Shusen
Ng, Ting-Ying
Feng, Yi
Sun, Guofang
Yan, Iris Renfei
Shao, Zhimin
BREAST CANCER RESEARCH AND TREATMENT, 2021, 187 (03) : 759 - 768
[27] Development of trastuzumab emtansine (Kadcyla®) for thetreatment of HER2-positive breast cancer
Phillips, Gail
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2015, 250
[28] Trastuzumab emtansine (T-DM1) versus trastuzumab in Chinese patients with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy for HER2-positive breast cancer in the phase 3 KATHERINE study
Chiun-Sheng Huang
Youngsen Yang
Ava Kwong
Shin-Cheh Chen
Ling-Ming Tseng
Mei-Ching Liu
Kunwei Shen
Shusen Wang
Ting-Ying Ng
Yi Feng
Guofang Sun
Iris Renfei Yan
Zhimin Shao
Breast Cancer Research and Treatment, 2021, 187 : 759 - 768
[29] Profiling and targeting HER2-positive breast cancer using trastuzumab emtansine
Sadeghi, Saeed
Olevsky, Olga
Hurvitz, Sara A.
PHARMACOGENOMICS & PERSONALIZED MEDICINE, 2014, 7 : 329 - 338
[30] Trastuzumab emtansine: a game changer in HER2-positive early breast cancer
Mano, Max S.
FUTURE ONCOLOGY, 2020, 16 (32) : 2595 - 2609

← 1 2 3 4 5 →